Evidence map›Paper›PMID 34739822›Full record

ArticleStructure (London, England : 1993)2021

Exciting new tools for studying TREM2 in dementia.

Georgina E Menzies, Megan Torvell

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Structure (London, England : 1993), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Georgina E MenziesDementia Research Institute and School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum Avenue, Cardiff CF10 3AT, UK.
Megan TorvellDementia Research Institute and Department of Immunology and Infection, School of Medicine, Cardiff University, CF24 4HQ, UK. Electronic address: menziesg@cardiff.ac.uk.
Cardiff University · GBUK Dementia Research Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TREM2 has long been implicated as an Alzheimer's disease (AD) risk gene. In this issue of Structure, Szykowska et al. (2021) generate antibody single-chain variable fragments (scFvs) to the immunoglobulin(Ig)-like domain of human TREM2. They present two co-crystalized structures and characterize the functional impact of these scFvs on TREM2.

Indexed as

Alzheimer DiseaseHumansMembrane GlycoproteinsReceptors, ImmunologicMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, human

Identifiers

PMID34739822
OpenAlexW3210741208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.